- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07792928
A Phase 1 Study to Evaluate the Safety and Effects of a Single Dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults.
25 sierpnia 2026 zaktualizowane przez: Shanghai Peptidstar Therapeutics Limited
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) After Single Administration in Healthy Adult Participants.
The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants.
The main parameters it aims to answer are: Does a single dose of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in healthy participants impact the Safety, Tolerability, Pharmacokinetics, and Immunogenicity profiles?
This study will be a - randomized, double blind, placebo-controlled study.
Przegląd badań
Status
Jeszcze nie rekrutacja
Warunki
Typ studiów
Interwencyjne
Zapisy (Szacowany)
40
Faza
- Faza 1
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Kontakt w sprawie studiów
- Nazwa: Laura E Elliot, MBCHb
- Numer telefonu: +64 9 242 3321
- E-mail: laura.elliott@momcr.co.nz
Lokalizacje studiów
-
-
Auckland
-
Takapuna, Auckland, Nowa Zelandia, 0622
- Momentum Clinical Research (MCR)
-
Kontakt:
- Laura E Elliot, MBCHb
- Numer telefonu: +64 9 242 3321
- E-mail: laura.elliott@momcr.co.nz
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
Akceptuje zdrowych ochotników
Tak
Opis
Inclusion Criteria:
- Body weight ≥ 50 kg for males and ≥ 45 kg for females, and body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.
- In good general health as determined by medical history, vital signs, physical examination, 12-lead ECG, laboratory tests (including hematology, blood biochemistry, coagulation function tests, urinalysis, stool routine tests), chest X-ray, etc., with results either within normal limits or assessed by the investigator as not clinically significant.
- Has been fully informed about the study, voluntarily agrees to participate, and has signed the ICF.
- The participant and their sexual partner(s) have no plans for conception from 2 weeks before screening until 6 months after the last dose of the investigational product, and agree to voluntarily using one or more highly effective non-pharmacological contraceptive methods and no intention of donating sperm or eggs during this period.
Exclusion Criteria:
- History or presence of immunological diseases.
- Women who are pregnant or are breastfeeding.
- Any prior or current disease or abnormality that, in the investigator's judgment, is clinically significant and may interfere with the conduct or interpretation of the study, including but not limited to neurological, cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, oncologic, pulmonary, immunological, psychiatric, or cerebrovascular conditions.
- Individuals who smoked, consumed coffee, St. John's Wort (hypericum perforatum), grapefruit, pomelo juice, or cranberry juice, and/or engagement in strenuous physical activity within 24 hours prior to dosing, which in the opinion of the investigator may affect drug absorption, distribution, metabolism, or excretion.
- Suspected or known allergy to any component of the investigational product, or any documented history of allergies
- Previous surgical procedures that may affect the results of the clinical study or gastric/abdominal surgery that may impact oral drug absorption; or recent major gastric/abdominal surgery of any kind within 12 weeks prior to screening or during study. With the exception of minor surgeries that in the opinion of the investigator/medical monitor, such as excision of subcutaneous lipomas.
- Having taken any prescription medication, over-the-counter drug, herbal medicine, or dietary supplement within 14 days prior to dosing or within five half-lives of the first administration, except for the condition without impact on the study outcomes as determined by the investigator. Occasional paracetamol less than 1000 mg for minor ailments is permitted if required.
- Non-physiological blood loss or donation of more than 400 mL of blood within 2 months prior to screening, receipt of a blood transfusion within 2 months prior to screening; or plans to donate blood during the study or within 60 days after the last dose.
- Participation in any investigational drug or medical device clinical trial with administration of the investigational product or device intervention within 3 months or five half-lives prior to screening.
- History of alcohol abuse, or consumption of more than 14 alcohol units per week within 6 months prior to screening , or unwillingness to abstain from alcohol during the study, or a positive alcohol test at screening.
- History of smoking (average daily cigarette consumption ≥ 5 cigarettes within 3 months prior to screening) or unwillingness to abstain from smoking during the study.
- History of drug abuse, use of illicit drugs within 3 months prior to the study, or a positive urine drug screen.
- Infection (including chronic or localized infection) within 7 days prior to screening, or a history of recurrent infections with underlying conditions predisposing to infections, or a history of opportunistic infections.
- Positive test result for any of the following: hepatitis B surface antigen, syphilis-specific antibody, hepatitis C antibody, or human immunodeficiency virus antibody.
- Those who have received any vaccine within 1 month prior to screening, or who are scheduled to receive any vaccine during the study or within 1 month after study completion.
- Having any other factors that, in the opinion of the investigator, may affect the study results or interfere with the participant's participation in the clinical study.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie dla jednej grupy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: HCXT-2001 Tablets - Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Eksperymentalny: HCXT-2001 Tablets - Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Komparator placebo: HCXT-2001 Tablets - Placebo Cohort 1
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Eksperymentalny: HCXT-2001 Tablets(A) - Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Eksperymentalny: HCXT-2001 Tablets(A) - Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Komparator placebo: HCXT-2001 Tablets(A) - Placebo Cohort 3
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Komparator placebo: HCXT-2001 Tablets - Placebo Cohort 2
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
|
Komparator placebo: HCXT-2001 Tablets(A) - Placebo Cohort 4
|
Two tablets taken orally in a fasted state
One tablet taken orally in a fasted state
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
|---|---|
|
Number of participants with AEs,SEAs, with abnormal - vital signs,physcial examinations,clinical laboratory results ,12-lead ECGs and stool routine tests
Ramy czasowe: Day 1 to Day 50
|
Day 1 to Day 50
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Maximum concentration of the drug (Cmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Time to maximum concentration (Tmax) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Area under the plasma concentration-time curve (AUC, including AUC0-t and AUC0-inf, etc.) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent volume of distribution (Vd/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Apparent clearance (CL/F) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A)
Ramy czasowe: Day 1 to day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to day 50
|
|
Plasma elimination half-life (t1/2) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Mean residence time (MRT) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Will be calculated using the non-compartmental analysis.
|
Day 1 to Day 50
|
|
Anti-drug antibodies (ADAs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Day 1 to Day 50
|
|
|
Neutralizing antibodies (Nabs) following a single oral dose of HCXT-2001 tablets and HCXT-2001 tablets(A).
Ramy czasowe: Day 1 to Day 50
|
Day 1 to Day 50
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Współpracownicy
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
14 sierpnia 2026
Zakończenie podstawowe (Szacowany)
10 listopada 2026
Ukończenie studiów (Szacowany)
10 listopada 2026
Daty rejestracji na studia
Pierwszy przesłany
25 sierpnia 2026
Pierwszy przesłany, który spełnia kryteria kontroli jakości
25 sierpnia 2026
Pierwszy wysłany (Rzeczywisty)
28 sierpnia 2026
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
28 sierpnia 2026
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
25 sierpnia 2026
Ostatnia weryfikacja
1 lipca 2026
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- HCXT-2001-PS-1-02
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Nie
Bada produkt urządzenia regulowany przez amerykańską FDA
Nie
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .